{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:07Z","timestamp":1789656007889,"version":"4.0.1"},"reference-count":51,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,2,15]]},"DOI":"10.2169\/internalmedicine.5097-20","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:06:15Z","timestamp":1602021975000},"page":"545-552","source":"Crossref","is-referenced-by-count":6,"title":["Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma"],"prefix":"10.2169","volume":"60","author":[{"given":"Maito","family":"Suoh","sequence":"first","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Taira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6: 18, 2014.","DOI":"10.1186\/2045-824X-6-18"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621-630, 2015.","DOI":"10.1056\/NEJMoa1406470"},{"key":"3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"3. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163-1173, 2018.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"4","unstructured":"4. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>\u2020<\/sup>. Ann Oncol 30: 1856-1883, 2019."},{"key":"5","unstructured":"5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68: 723-750, 2018."},{"key":"6","unstructured":"6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69: 182-236, 2018."},{"key":"7","unstructured":"7. Eisai Co., Ltd. LENVIMA Interview Form (10th edition) [Internet]. [cited 2020 Jul 30]. Available from: https:\/\/medical.eisai.jp\/content\/000004672.pdf (in Japanese)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Snape WJ. Duodenal ulcer as an occasional etiologic factor in obstructive jaundice. Ann Intern Med 42: 1001-1010, 1995.","DOI":"10.7326\/0003-4819-42-5-1001"},{"key":"9","unstructured":"9. Dagradi AE, Schindler R. Pancreatic insufficiency and obstructive jaundice due to chronic duodenal ulcer: a case report. Am J Gastroenterol 32: 708-713, 1959."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Luman W, Hudson N, Choudari CP, Eastwood MA, Palmer KR. Distal biliary stricture as a complication of sclerosant injection for bleeding duodenal ulcer. Gut 35: 1665-1667, 1994.","DOI":"10.1136\/gut.35.11.1665"},{"key":"11","unstructured":"11. Ho CY, Chen TS, Chang FY, Lee SD. Benign nontraumatic inflammatory stricture of mid portion of common bile duct mimicking malignant tumor: report of two cases. World J Gastroenterol 10: 2153-2155, 2004."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hidalgo L, Repiso A, Romero M, et al. Obstructive jaundice as a complication of a peptic duodenal ulcer mimicking pancreatic cancer. Endoscopy 42 (Suppl 2): E294-E295, 2010.","DOI":"10.1055\/s-0030-1255785"},{"key":"13","unstructured":"13. Tran B, Dunning K, Kohli H. QUIZ HQ 55. Unusual cause of obstructive jaundice and cholangitis. J Gastrointestin Liver Dis 19: 75-92, 2010."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Crismale JF, Ward SC, Ahmad J. An unusual cause of abdominal pain and biliary obstruction in a patient with hepatocellular carcinoma. Gastroenterology 154: e18-e19, 2018.","DOI":"10.1053\/j.gastro.2017.08.041"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.","DOI":"10.1055\/s-0030-1247132"},{"key":"16","unstructured":"16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009."},{"key":"17","unstructured":"17. Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci 25: 17-30, 2018."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795, 2007.","DOI":"10.1038\/sj.bjc.6603813"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26: 393-397, 2008.","DOI":"10.1007\/s10637-008-9125-4"},{"key":"20","unstructured":"20. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10: 559-568, 2009."},{"key":"21","unstructured":"21. Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 48: 1126-1132, 2012."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep 14: 277-284, 2012.","DOI":"10.1007\/s11912-012-0238-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K. Bevacizumab safety in Japanese patients with colorectal cancer. Jpn J Clin Oncol 46: 234-240, 2016.","DOI":"10.1093\/jjco\/hyv182"},{"key":"24","unstructured":"24. Wang Z, Zhang J, Zhang L, Liu P, Xie Y, Zhou Q. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. J Chemother 28: 328-334, 2016."},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 14: 135-141, 2011.","DOI":"10.1007\/s10456-010-9197-6"},{"key":"26","unstructured":"26. Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 89: 394-403, 2014."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Date E, Okamoto K, Fumita S, Kaneda H. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Invest New Drugs 36: 350-353, 2018.","DOI":"10.1007\/s10637-017-0522-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Suzuki N, Tajiri K, Futsukaichi Y, et al. Perforation of the small intestine after introduction of lenvatinib in a patient with advanced hepatocellular carcinoma. Case Rep Gastroenterol 14: 63-69, 2020.","DOI":"10.1159\/000505774"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet 374: 1449-1461, 2009.","DOI":"10.1016\/S0140-6736(09)60938-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 19: 1673-1682, 2013.","DOI":"10.3748\/wjg.v19.i11.1673"},{"key":"31","unstructured":"31. ClinicalTrials.gov. A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of participants with unresectable hepatocellular carcinoma [Internet]. [cited 2020 Jul 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01761266"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Inomata A, Nakano-Ito K, Fujikawa Y, et al. Brunner&apos;s gland lesions in rats induced by a vascular endothelial growth factor receptor inhibitor. Toxicol Pathol 42: 1267-1274, 2014.","DOI":"10.1177\/0192623313520350"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290: H560-H576, 2006.","DOI":"10.1152\/ajpheart.00133.2005"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yang Y, Zhang Y, Cao Z, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A 110: 12018-12023, 2013.","DOI":"10.1073\/pnas.1301331110"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 45: 1005-1019, 1997.","DOI":"10.1177\/002215549704500710"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci 37: 1081-1096, 2016.","DOI":"10.1016\/j.tips.2016.10.003"},{"key":"37","unstructured":"37. Danopoulos S, Schlieve CR, Grikscheit TC, Al Alam D. Fibroblast growth factors in the gastrointestinal tract: twists and turns. Dev Dyn 246: 344-352, 2017."},{"key":"38","unstructured":"38. Fukuhara K, Terakura M, Katsuragi K. Severe gastric and duodenal ulcer after chemotherapy of mFOLFOX6 and bevacizumab. Gan To Kagaku Ryoho 38: 457-459, 2011 (in Japanese, Abstract in English)."},{"key":"39","unstructured":"39. Kameda R, Ueno M, Kobayashi S, Ohkawa S. A case of multiple ulcers in the descending part of the duodenum following sorafenib administration for hepatocellular carcinoma. Gastroenterological Endoscopy 53: 1809-1815, 2011 (in Japanese, Abstract in English)."},{"key":"40","unstructured":"40. Uchino T, Mishima H, Kimura K, et al. Four cases of bevacizumab-related gastrointestinal perforation. Gan To Kagaku Ryoho 41: 2506-2508, 2014 (in Japanese, Abstract in English)."},{"key":"41","unstructured":"41. Horibe Y, Adachi S, Okuno M, et al. A refractory duodenal ulcer with a biliary-duodenal fistula following the administration of bevacizumab. Nihon Shokakibyo Gakkai Zasshi 113: 1244-1250, 2016 (in Japanese, Abstract in English)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Palmela C, Gouveia C, Fidalgo C, Ferreira AO. Rare case of a giant duodenal ulcer penetrating the pancreas during antiangiogenic treatment. BMJ Case Rep 12: e228612, 2019.","DOI":"10.1136\/bcr-2018-228612"},{"key":"43","unstructured":"43. Mayumi T, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci 25: 96-100, 2018."},{"key":"44","unstructured":"44. Tsuyuguchi T, Takada T, Kawarada Y, et al. Techniques of biliary drainage for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 14: 35-45, 2007."},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Ryozawa S, Itoi T, Katanuma A, et al. Japan Gastroenterological Endoscopy Society guidelines for endoscopic sphincterotomy. Dig Endosc 30: 149-173, 2018.","DOI":"10.1111\/den.13001"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 26: 1-14, 2014.","DOI":"10.1111\/den.12183"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 67: 1033-1041, 2018.","DOI":"10.1136\/gutjnl-2017-314852"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 14: 529-534, 2000.","DOI":"10.1046\/j.1365-2036.2000.00739.x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Takahashi A, Moriguchi M, Seko Y, et al. Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma. Anticancer Res 39: 5149-5156, 2019.","DOI":"10.21873\/anticanres.13710"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Kuzuya T, Ishigami M, Ito T, et al. Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 50: 374-381, 2020.","DOI":"10.1111\/hepr.13452"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Kaneko S, Tsuchiya K, Kurosaki M, et al. Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatol Res 50: 137-143, 2020.","DOI":"10.1111\/hepr.13416"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5097-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T03:49:24Z","timestamp":1613792964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/4\/60_5097-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5097-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}